PHILADELPHIA, Pa., May 22 /PRNewswire/ -- The first product that
effectively manages the symptoms of tardive dyskinesia (TD) in men will be
introduced in the U.S. today by SHS North America during the 155th Annual
American Psychiatric Association Meeting in Philadelphia. TARVIL(TM), by the
use of the branched chain amino acids (BCAA), decreases symptoms of TD, a
neurological disorder that is secondary to the anti-psychotic medications used
to treat severe mental illness such as schizophrenia. TD symptoms can range
from mild to severe based on the frequency and intensity of involuntary
abnormal movements of the face, mouth and extremities. TD symptoms can
include repetitive movements of the tongue, such as protrusions; of the jaw,
such as chewing; and of the fingers, such as flicking. In severe states,
movements, such as tongue protrusions, can be seen at the rate of 10 per
TD affects as many as 1 million people in the U.S. who receive treatment
with anti-psychotic medications.
Clinical research findings have shown that a decreased ability to clear
the amino acid phenylalanine from the plasma is associated with symptoms of TD
in men. It is also known that ingestion of BCAA reduces plasma levels of
phenylalanine and its availability to the brain. A lead study presented today
at the APA by Mary Ann Richardson, PhD, Director of the Movement Disorders and
Molecular Psychiatric Division of the Nathan S. Kline Institute of Psychiatric
Research, New York State Office of Mental Health in Orangeburg, NY,
demonstrates that ingestion of the BCAA-based medical food TARVIL increases
plasma BCAA levels, decreases plasma levels of phenylalanine and significantly
reduces TD symptoms.
"Oftentimes, symptoms of TD are so disfiguring that this disorder
alienates patients and their families and they are reluctant to go out in
public," said Mark De Fries, CEO of SHS North America. "Patients with severe
TD can now use TARVIL and reduce these unwanted movements without stopping
their anti-psychotic medications."
Studies have determined that TD develops in 15 to 20 percent of patients
taking anti-psychotic medications for several years. "In many cases, TD
symptoms continue even after anti-psychotic medication is stopped," said De
Fries. "TARVIL will relieve a lot of patients, especially those who are
institutionalized with serious psychotic conditions."
TARVIL is a powdered drink mix with a pineapple flavor. Recommended usage
under guidance of a physician is three times a day with intake amounts
dependent on the patient's body weight and medical condition.
SHS North America, located in Rockville, MD, is a recognized world leader
in specialized clinical nutrition. The company markets and distributes
medical foods for the dietary management of metabolic, allergic,
gastrointestinal and neurological disorders. Other products include
Neocate(R), an amino acid-based, hypoallergenic infant formula for cow milk
allergy and multiple food protein intolerance; Periflex(R) and Phlexy-10(R),
both medical foods for the dietary management of phenylketonuria (PKU); and
KetoCal(TM), a nutritionally complete ketogenic formula for individuals over
the age of one year with intractable epilepsy.
For more information, visit http://www.tarvil.com or call 1-877-482-7845.
MAKE YOUR OPINION COUNT - Click Here
SOURCE SHS North America